Login / Signup

VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients.

Takahiro HorieKoh Ono
Published in: European heart journal. Cardiovascular pharmacotherapy (2024)
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • stem cells
  • mesenchymal stem cells
  • genome editing
  • replacement therapy